EXTON, Pa.--(BUSINESS WIRE)-- Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will be presenting at The Wall Street Analyst Forum 22nd Annual Analyst Conference to be held on Tuesday, March 1, at The University Club (1 West 54th Street) in NYC.
Fibrocell’s presentation is scheduled for 12:05 p.m. Eastern Time.
The audio portion of the presentation will be webcast live, and a replay will be available on the Investors section of the Company's website at www.fibrocellscience.com.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (OTCBB: FCSC) is a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.
CONTACT:
Fibrocell Science, Inc.
David M. Pernock
President & CEO
Phone: (484) 713-6000
[email protected]
or
ICR, LLC
Sherry Bertner
Managing Director
Phone: (646) 277-1247
[email protected]
KEYWORDS: United States North America New York Pennsylvania
INDUSTRY KEYWORDS: Stem Cells Health Biotechnology General Health
MEDIA:
| Logo |